These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 23038122)

  • 1. Comparing bounds for vaccine effects on infectiousness.
    Halloran ME; Hudgens MG
    Epidemiology; 2012 Nov; 23(6):931-2. PubMed ID: 23038122
    [No Abstract]   [Full Text] [Related]  

  • 2. Bounding the infectiousness effect in vaccine trials.
    VanderWeele TJ; Tchetgen Tchetgen EJ
    Epidemiology; 2011 Sep; 22(5):686-93. PubMed ID: 21753730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Components of the indirect effect in vaccine trials: identification of contagion and infectiousness effects.
    Vanderweele TJ; Tchetgen Tchetgen EJ; Halloran ME
    Epidemiology; 2012 Sep; 23(5):751-61. PubMed ID: 22828661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Causal inference for vaccine effects on infectiousness.
    Halloran ME; Hudgens MG
    Int J Biostat; 2012 Jan; 8(2):. PubMed ID: 22499732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficiency of estimating vaccine efficacy for susceptibility and infectiousness: randomization by individual versus household.
    Datta S; Halloran ME; Longini IM
    Biometrics; 1999 Sep; 55(3):792-8. PubMed ID: 11315008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of vaccine field studies: types of effects and designs.
    Halloran ME
    J Biopharm Stat; 2006; 16(4):415-27. PubMed ID: 16892904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV-1 vaccines.
    Longini IM; Datta S; Halloran ME
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Dec; 13(5):440-7. PubMed ID: 8970471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing vaccine efficacy for the prevention of acute otitis media by pneumococcal vaccination in children: a methodological overview of statistical practice in randomized controlled clinical trials.
    Jahn-Eimermacher A; du Prel JB; Schmitt HJ
    Vaccine; 2007 Aug; 25(33):6237-44. PubMed ID: 17629378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Needle size for vaccination procedures in children and adolescents.
    Beirne PV; Hennessy S; Cadogan SL; Shiely F; Fitzgerald T; MacLeod F
    Cochrane Database Syst Rev; 2015 Jun; (6):CD010720. PubMed ID: 26086647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Booster vaccination with hexavalent DTPa-HBV-IPV/Hib vaccine in the second year of life is as safe as concomitant DTPa-IPV/Hib + HBV administered separately.
    Saenger R; Maechler G; Potreck M; Zepp F; Knuf M; Habermehl P; Schuerman L
    Vaccine; 2005 Jan; 23(9):1135-43. PubMed ID: 15629356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statistical considerations for noninferiority/equivalence trials in vaccine development.
    Wang WW; Mehrotra DV; Chan IS; Heyse JF
    J Biopharm Stat; 2006; 16(4):429-41. PubMed ID: 16892905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of vaccine equivalence/non-inferiority trials with correlated multiple binomial endpoints.
    Kong L; Kohberger RC; Koch GG
    J Biopharm Stat; 2006; 16(4):555-72. PubMed ID: 16892913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing vaccines: a systematic review of the use of the non-inferiority margin in vaccine trials.
    Donken R; de Melker HE; Rots NY; Berbers G; Knol MJ
    Vaccine; 2015 Mar; 33(12):1426-32. PubMed ID: 25659273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccines for preventing typhoid fever.
    Anwar E; Goldberg E; Fraser A; Acosta CJ; Paul M; Leibovici L
    Cochrane Database Syst Rev; 2014 Jan; (1):CD001261. PubMed ID: 24385413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maximizing statistical power in group-randomized vaccine trials.
    Riggs T; Koopman JS
    Epidemiol Infect; 2005 Dec; 133(6):993-1008. PubMed ID: 16274496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine clinical trials--a statistical primer.
    Mehrotra DV
    J Biopharm Stat; 2006; 16(4):403-14. PubMed ID: 16892903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statistical aspects of fish vaccination trials.
    Jarp J; Tverdal A
    Dev Biol Stand; 1997; 90():311-20. PubMed ID: 9270859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A stochastic model of vaccine trials for endemic infections using group randomization.
    Riggs TW; Koopman JS
    Epidemiol Infect; 2004 Oct; 132(5):927-38. PubMed ID: 15473157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ON THE USE OF NONPARAMETRIC BOUNDS FOR CAUSAL EFFECTS IN NULL RANDOMIZED TRIALS.
    Gabriel EE; Sachs MC
    Am J Epidemiol; 2021 Oct; 190(10):2231. PubMed ID: 34017983
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.